Summary:
A June 12, 2026 release from the Office of the Director of National Intelligence (ODNI) under Director Tulsi Gabbard has publicly confirmed the existence of more than 120 U.S.-funded biological laboratories in over 30 countries, following the declassification of key intelligence and supporting documentation. The evidence details the construction, funding, and operation of these labs, with over 40 located in Ukraine. These Ukrainian facilities store and research a range of dangerous pathogens such as Anthrax, Ebola, Marburg, Lassa, Plague, MERS, and SARS. Intelligence assessments highlight acute security vulnerabilities, particularly in Ukraine, where ongoing conflict has raised the risk of Russian attack or seizure. The declassified materials also reveal that some labs engaged in gain-of-function research with limited oversight, and that clinical trials conducted at these sites have raised significant ethical, financial, and regulatory concerns. Oversight gaps and fragmented accountability structures are documented, with some labs lacking finalized permits for pathogen work.
Detailed Report
1. Global Network of U.S.-Funded Biolabs
The ODNI’s June 12, 2026 statement, supported by newly declassified intelligence, confirms that the United States has funded and supported more than 120 biological laboratories across over 30 countries. These facilities were established under various cooperative threat reduction and public health initiatives, but the full extent of U.S. involvement had not been previously acknowledged in public forums. The declassified evidence includes detailed inventories, funding records, and operational summaries for these laboratories, revealing a global footprint far larger than previously reported by official sources.
2. Extensive U.S.-Funded Biolab Network in Ukraine
According to the declassified intelligence, over 40 laboratories in Ukraine have been built or supported with U.S. funding since the early 2000s. Facilities such as the Kherson Diagnostic Laboratory, Kherson Oblast Laboratory Center, Institute of Veterinary Medicine of the National Academy of Agrarian Sciences, Central Reference Laboratory, and Ukrainian Research Antiplague Institute are specifically named. U.S. contractors, including Black & Veatch, managed construction and equipment procurement, with individual lab costs ranging from $1.7 million to over $2.1 million.
3. Storage and Research of Dangerous Pathogens
The Ukrainian biolabs serve as repositories for a wide array of dangerous pathogens, including Anthrax, tularemia, tuberculosis, African Swine Fever, Newcastle Disease, MERS, SARS, Marburg, Ebola, Lassa, Plague, and Rickettsia. Some of these agents are remnants of the Soviet-era biological weapons program, while others are the focus of ongoing research and surveillance. The presence of these pathogens has been corroborated by multiple independent sources, including the World Health Organization, which advised Ukraine to destroy high-threat pathogen stocks at the onset of the Russian invasion to prevent accidental or deliberate release.
4. Intelligence Community Warnings on Security Vulnerabilities
Declassified intelligence assessments have repeatedly warned that U.S.-funded biolabs in Ukraine are vulnerable to Russian military action, including the risk of attack, seizure, or accidental damage during the ongoing conflict. The ODNI’s internal analysis identified the risk that dangerous pathogens could be released, stolen, or misused if Russian forces gained access to these facilities. Emergency protocols, including the destruction of certain pathogen stocks, were enacted in response to these threats, as confirmed by the WHO and U.S. State Department.
5. Gain-of-Function Research and Oversight Deficiencies
The declassified materials reveal that some U.S.-funded overseas labs, including those in Ukraine, have engaged in gain-of-function research—experiments that increase the transmissibility or virulence of pathogens—with minimal external oversight. Internal reviews criticized the lack of transparency and accountability for such research, noting that oversight mechanisms were often fragmented across multiple U.S. agencies and that physical inspections were infrequent, especially in conflict zones.
6. Ethical, Financial, and Security Concerns in Clinical Trials
Clinical trials conducted at U.S.-funded overseas biolabs have raised significant ethical, financial, and security concerns. Issues include the adequacy of informed consent, the protection of vulnerable populations, and the risk of exploitation in low- and middle-income countries. The rapid expansion of research activities has often outpaced the development of local oversight mechanisms, leading to concerns about participant protections and the fair distribution of benefits. Financial risks include unclear accounting for pathogen research, contractor and subcontractor vulnerabilities, and the potential for waste, fraud, and abuse.
7. Oversight and Regulatory Gaps Documented
The ODNI declassification and supporting Government Accountability Office reports highlight persistent oversight gaps in the management of U.S.-funded overseas biolabs. Regulatory frameworks are fragmented among multiple agencies, and some Ukrainian labs were still awaiting permits to work with dangerous pathogens as of 2026. Limited on-the-ground monitoring and infrequent audits have further complicated efforts to ensure compliance with biosafety and ethical standards.
Conclusion
The June 2026 ODNI declassification provides the most comprehensive public accounting to date of the U.S. government’s global biolab program. The evidence confirms a vast network of more than 120 U.S.-funded labs, including over 40 in Ukraine, many of which store and research dangerous pathogens. Acute security vulnerabilities, oversight deficiencies, and ethical concerns have been documented, underscoring the need for enhanced transparency, robust oversight, and international cooperation to mitigate risks associated with high-containment biological research.